Invest in

Drug-Patent Cliffs

12.8%
8.6%
0.0%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
12.8%
8.6%
0.0%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 7.9%
20.9% Taro Pharmaceutical Industries Ltd. TARO 19.4%
19.7% Dr. Reddy's Laboratories Ltd RDY 14.4%
16.0% Mylan N.V. MYL 9.8%
10.6% The Medicines Company MDCO 52.4%
9.5% Abbott Laboratories ABT 12.0%
8.2% Akorn Inc. AKRX 15.0%
3.7% Lannett Co Inc LCI 2.3%
3.4% Impax Laboratories Inc. IPXL 73.1%
3.4% Teva Pharmaceutical Industries Limited American Depositary Share TEVA 38.7%
2.8% Mallinckrodt plc MNK 27.9%
1.1% Cambrex Corporation CBM 19.8%
0.9% Endo International PLC ENDP 67.0%

Quotes delayed 15 mins. Currently Mar 23, 2017 4:10:51 AM. Fields are marked with -- when data is unavailable.